George Morris, chief operations officer at ValiRx Plc (LON:VAL) tells Proactive the've been given the go-ahead by regulators to expand and accelerate their early-stage cancer study.
The Medicines and Healthcare Regulator Agency and Research Ethics Committee are allowing them to substantially raise the dosing of VAL201, a treatment for metastatic prostate cancer and other solid tumours.
They'll be doing this to find the correct therapeutic levels of treatment to administer in order to try to stop the disease’s spread.
